Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Present ALLHAT Analysis At Advisory Committee On Antihypertensive Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will present a non-inferiority analysis suggesting Norvasc (amlodipine) is similar to the diuretic chlorthalidone in preventing hypertension outcomes during a June 15 meeting of FDA's Cardiovascular & Renal Drugs Advisory Committee, the agency says.

You may also be interested in...



Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says

Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.

Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says

Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.

FDA Proposes Antihypertensive Class Indication For Reducing CV Events

Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel